| [1] |
徐悦，郑波. 乳腺癌治疗相关血液肿瘤的临床研究进展[J]. 肿瘤，2017，37(10):1106-1111.
|
| [2] |
Santo AE, Chacim S, Ferreira I, et al. Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia[J]. Oncol Lett, 2016, 12(1):262-268.
|
| [3] |
Wolff AC, Blackford AL, Visvanathan K, et al. Risk of marrow neoplasms after adjuvant breast cancer therapy：the national comprehensive cancer network experience[J]. J Clin Oncol, 2015, 33(4):340-348.
|
| [4] |
李哲，李斌. 实体瘤迭合白血病12例分析[J]. 现代预防医学，2013, 40(3):600-601.
|
| [5] |
许明录，汤波. DNA拓扑异构酶Ⅰ和Ⅱ的结构特性及抑制剂的研究进展 [J]. 河南科技学院学报，2009, 37(2):32-38.
|
| [6] |
杨喜晶，周福平，张迁，等. 化疗药物治疗双原发肿瘤继发急性白血病1例及文献复习[J]. 药学实践杂志，2017, 33(5):453-456.
|
| [7] |
Praga C, Bergh J, Bliss J，et al.Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide[J]. J Clin Oncol，2005，23(18): 4179-4191.
|
| [8] |
Kaplan H, Malmgren J, De Roos A. Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study [J]. Breast Cancer Res Treat, 2013, 137(3):863-867.
|
| [9] |
张春来．G-CSF动员健康外周血造血干细胞捐献者诱发白血病风险研究进展 [J]．中国输血杂志，2012, 25(11):1132-1134.
|
| [10] |
Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy [J]. J Natl Cancer Inst, 2007, 99(3):196-205.
|
| [11] |
贾晓青，柳光宇．克服乳腺癌内分泌耐药的靶向治疗新进展 [J]. 肿瘤，2013, 33(1):91-96.
|
| [12] |
Sevcikova K, Zhuang Z, Garcia-Manero G, et al. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment [J]. Leukemia, 2016, 30(1):242-247.
|
| [13] |
Churpek JE, Marquez R, Neistadt B, et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia[J]. Cancer, 2016, 122(2):304-311.
|
| [14] |
Verkooijen HM, Fioretta G, Rapiti E，et al. Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: results from a population-based study[J]．Int J Cancer，2008，122(5): 1114-1117.
|
| [15] |
Martin MG, Welch JS, Luo J，et al. Therapy related acute myeloid leukemia in breast cancer survivors，a population-based study[J]．Breast Cancer Res Treat，2009，118(3):593-598.
|
| [16] |
Borthakur G, ahdab SE, Radanvi F，et al.Activity of decitabine in atients with myelodysplastic syrndrome previously treated with azacitidin[J]．Leuk Lymphoma，2008，49(4):690-695.
|
| [17] |
Braun T, Droin N, Itzykson R，et al. 162 A phase Ⅱ study of decit-abine in advanced chronic myelomonocytic leukemia (CMML)[J]．Leuk Res，2011，35: S63-S64.
|
| [18] |
Wijermans PW, Lübbert M, Verhoef G，et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients[J]. Ann Hematol，2005，84 Suppl 1: 9-17.
|
| [19] |
杨华，朱海燕，姜孟孟，等. 地西他滨治疗骨髓增生异常综合征和急性髓系白血病的临床观察[J]. 中国实验血液学杂志，2013，21(1):121-125.
|
| [20] |
夏乐敏，薛城，姜一陵，等．超小剂量地西他滨治疗慢性粒单核细胞白血病1例[J]．临床血液学杂志，2018，31(5):383-384.
|